About Eric Richman
Eric Richman is CEO and director at Tempo Therapeutics.
Eric Richman reports to the SEC as a director or officer of 5 public companies, including Gain Therapeutics (GANX), NeuBase Therapeutics (NBSE) and Adma Biologics (ADMA).
Eric Richman first appears on SEC filings in 2007.
Experience
This experience comes from Eric Richman's profile and from SEC filings. For roles taken from filings, the years are when the filings name Eric Richman in the role, so the role may have started earlier or lasted longer.
SA
SafeHeal Current
Independent Director
2025 – Present
Tempo Therapeutics, Inc. Current
Director and Interim CEO (2024 – Present)
Director
2024 – Present · San Diego, CA
Develops synthetic materials to help patients regenerate tissue after surgery.
PO
PolarityBio Current
Independent Director
2024 – Present
MH
MicroHealth (digital hematology) Current
Independent Director
2023 – Present
LA
LabConnect Current
Independent Director
2017 – Present
GI
Gain Therapeutics, Inc.
Chief Executive Officer and director
2020 – 2025 · Public company (GANX)
HH
Horizon Infusions / InFuse Holdings
Director & Co-Founder
2019 – 2025
NI
NeuBase Therapeutics, Inc.
Director
2019 – 2022 · Public company (NBSE)
AI
Adma Biologics, Inc.
Director
2008 – 2020 · Public company (ADMA)
BC
Brace Pharma Capital
Venture Partner
2016 – 2018
PI
PharmAthene, Inc.
President & CEO
2010 – 2017
AI
Altimmune, Inc.
President and CEO, director
2007 – 2016 · Public company (ALT)
AB
American Bank
Director
2009 – 2013
LI
Lev Pharmaceuticals Inc
Director
2004 – 2008 · Public company (LEVP)
ST
SIGA Technologies
Director
2000 – 2001
MI
MedImmune, Inc.
Director, International Commercialization
1988 – 2000
HL
HealthCare Ventures LLC
Associate
1987 – 1988
Key Colleagues at Startups
The people Eric Richman works with at each company, as listed on that company's latest Form D.
Tempo Therapeutics, Inc. · Form D, Sep 11, 2026
Donald Griffin
Founder & CSO, director
Steven Sands
Chairman
Westbrook Weaver
Founder & CTO, director
Biren Mehta
Director